NCT06091215 is a NA clinical trial of Sciton Joule System in Pigment Skin, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT06091215?

NCT06091215 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT06091215?

Interventions in NCT06091215: Sciton Joule System.

What condition does NCT06091215 study?

NCT06091215 studies Pigment Skin.

Is NCT06091215 still recruiting?

NCT06091215 is currently completed. Last updated 27 January 2026.

Are results published for NCT06091215?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-27 · How we verify

NCT06091215

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combining Broad Based Light (BBL), Fractionated 1927 (MOXI) and Dual Wavelength 2940/1470 (HALO)

Completed NA Results posted Last updated 27 January 2026

What this trial tests

NA trial testing Sciton Joule System in Pigment Skin in 15 participants. Completed in 31 December 2024.

Timeline

1 January 2024

Primary endpoint
11 June 2024

31 December 2024

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 January 2024
Primary completion	11 June 2024
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Sciton Joule System

Conditions studied

Pigment Skin — all drugs for Pigment Skin →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 20 to 75, any sex, with Pigment Skin. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Brown Spots at 1 Month From Baseline (Single Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement

Front

Group	Value	95% CI
Single Treatment Arm	12.00	-2.00 – 17.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	5.00	-11.00 – 7.00

Nose

Group	Value	95% CI
Single Treatment Arm	0.00	-3.00 – 1.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	5.00	-11.00 – 5.00

Change in Brown Spots at 3 Months From Baseline (Single Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement

Front

Group	Value	95% CI
Single Treatment Arm	8.00	6.00 – 12.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	.00	-2.00 – 25.00

Nose

Group	Value	95% CI
Single Treatment Arm	3.00	-1.00 – 5.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	9.00	-2.00 – 25.00

Change in Brown Spots at 1 Month From Baseline (Double Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement

Front

Group	Value	95% CI
Double Treatment Arm	-2.00	-14.00 – 0.50

Left Oblique

Group	Value	95% CI
Double Treatment Arm	-3.50	-9.00 – -0.50

Nose

Group	Value	95% CI
Double Treatment Arm	-2.00	-4.50 – -0.50

Right Oblique

Group	Value	95% CI
Double Treatment Arm	-2.50	-16.50 – 12.50

Change in Brown Spots at 3 Months From Baseline (Double Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall UV spots using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement

Front

Group	Value	95% CI
Double Treatment Arm	-0.50	-12.00 – 9.00

Left Oblique

Group	Value	95% CI
Double Treatment Arm	-4.00	-9.50 – 6.50

Nose

Group	Value	95% CI
Double Treatment Arm	-0.50	-3.50 – 1.50

Right Oblique

Group	Value	95% CI
Double Treatment Arm	8.50	-14.00 – 22.50

Change in Pores at 1 Month From Baseline (Single Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Single Treatment Arm	-5.00	-11.00 – 10.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	-5.00	-13.00 – 17.00

Nose

Group	Value	95% CI
Single Treatment Arm	-11.00	-21.00 – 3.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	-3.00	-7.00 – 10.00

Change in Pores at 3 Months From Baseline (Single Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Single Treatment Arm	1.00	-34.00 – 14.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	-1.00	-6.00 – 17.00

Nose

Group	Value	95% CI
Single Treatment Arm	1.00	-15.00 – 5.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	-7.00	-21.00 – 3.00

Change in Pores at 1 Month From Baseline (Double Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement

Front

Group	Value	95% CI
Double Treatment Arm	2.50	-41.00 – 23.50

Left Oblique

Group	Value	95% CI
Double Treatment Arm	-27.50	-72.00 – 10.00

Nose

Group	Value	95% CI
Double Treatment Arm	-10.00	-28.00 – -5.50

Right Oblique

Group	Value	95% CI
Double Treatment Arm	-17.00	-60.00 – 34.00

Change in Pores at 3 Months From Baseline (Double Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall pore count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Double Treatment Arm	-0.00	-0.00 – -0.00

Left Oblique

Group	Value	95% CI
Double Treatment Arm	-0.00	-0.00 – 0.00

Nose

Group	Value	95% CI
Double Treatment Arm	-0.00	-0.01 – 0.00

Right Oblique

Group	Value	95% CI
Double Treatment Arm	-0.00	-0.00 – 0.00

Change in Porphyrins at 1 Month From Baseline (Single Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Single Treatment Arm	17.00	-292.00 – 217.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	51.00	-381.00 – 331.00

Nose

Group	Value	95% CI
Single Treatment Arm	15.00	-49.00 – 66.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	4.00	-290.00 – 351.00

Change in Porphyrins at 3 Months From Baseline (Single Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Single Treatment Arm	-123.00	-365.00 – 272.00

Left Oblique

Group	Value	95% CI
Single Treatment Arm	-192.00	-446.00 – 99.00

Nose

Group	Value	95% CI
Single Treatment Arm	32.00	-19.00 – 88.00

Right Oblique

Group	Value	95% CI
Single Treatment Arm	-114.00	-420.00 – 136.00

Change in Porphyrins at 1 Month From Baseline (Double Treatment Group) Primary · Baseline, 1 Month

Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Double Treatment Arm	1.00	-312.00 – 395.50

Left Oblique

Group	Value	95% CI
Double Treatment Arm	164.50	-56.50 – 730.00

Nose

Group	Value	95% CI
Double Treatment Arm	45.50	-25.00 – 94.50

Right Oblique

Group	Value	95% CI
Double Treatment Arm	214.50	-39.50 – 789.50

Change in Porphyrins at 3 Months From Baseline (Double Treatment Group) Primary · Baseline, 3 Months

Quantitively assessment of change in overall porphyrins count using measurements provided VISIA 3D analysis on different sides of the face for all subjects A lower value signifies improvement.

Front

Group	Value	95% CI
Double Treatment Arm	-160.50	-266.00 – -1.00

Left Oblique

Group	Value	95% CI
Double Treatment Arm	-145.50	-263.00 – 158.50

Nose

Group	Value	95% CI
Double Treatment Arm	3.00	-66.00 – 60.00

Right Oblique

Group	Value	95% CI
Double Treatment Arm	13.00	-278.50 – 135.50

Sponsor's own description

This is a single-site, non-randomized, non-controlled study at UT Southwestern Medical Center at Dallas in the Department of Plastic Surgery. The study is designed to follow up to 15 consenting subjects who may receive up to 2 BBL/MOXI/HALO treatments under an IRB approved protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06091215 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06091215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT06091215

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other University of Texas Southwestern Medical Center trials

Verify against primary sources